Payment overview · 2025
General Payments
$85,684.76
265 reported records · 31 companies
Healthcare provider profile · identity verified
Samer Abbas, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · EAST CHICAGO, IN · NPI 1568481182
Verified facts
What the public records show
CMS Open Payments records show Samer Abbas, MD received $85,684.76 in general payments during 2025 across 265 reported records.
Medtronic, Inc. accounted for 48.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 60 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41,450.85 | 48.4% | 83 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16,851.28 | 19.7% | 34 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $12,711.29 | 14.8% | 15 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $7,134.92 | 8.3% | 24 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,760.74 | 2.0% | 18 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $1,323.13 | 1.5% | 10 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $702.77 | 0.8% | 5 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $531.46 | 0.6% | 5 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $518.59 | 0.6% | 4 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $455.88 | 0.5% | 8 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $256.54 | 0.3% | 3 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $244.13 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $210.33 | 0.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $177.85 | 0.2% | 10 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $161.42 | 0.2% | 3 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $160.94 | 0.2% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $151.32 | 0.2% | 1 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $146.11 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $135.85 | 0.2% | 7 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $132.86 | 0.2% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $129.46 | 0.1% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $105.39 | 0.1% | 4 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $48.05 | 0.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $33.42 | 0.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.42 | 0.0% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $26.30 | 0.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.54 | 0.0% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $20.54 | 0.0% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $18.51 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.78 | 0.0% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $15.09 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,590.64 | 11 |
| Consulting Fee | $18,512.50 | 3 |
| Food and Beverage | $12,334.69 | 204 |
| Travel and Lodging | $10,246.93 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $40,862.98 | 71 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $13,040.20 | 3 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $11,875.00 | 5 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $6,330.40 | 14 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $1,640.24 | 17 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $1,163.40 | 9 | 2025 |
Source payment records
|
|||||
| LANGSTON Normalized: langston |
Device | Teleflex LLC | $857.14 | 2 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $804.52 | 10 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $571.95 | 5 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $531.46 | 5 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $531.46 | 5 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $531.46 | 5 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $531.46 | 5 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $531.46 | 5 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTCA Normalized: selution slr ptca |
Device | CORDIS US CORP. | $508.97 | 3 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $465.99 | 8 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $455.88 | 8 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $434.46 | 4 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $411.67 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $388.72 | 4 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $373.56 | 4 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $373.56 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $371.03 | 4 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $329.21 | 1 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $256.54 | 3 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $244.13 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $225.09 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $210.33 | 12 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $191.89 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $177.85 | 10 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $160.94 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $156.72 | 2 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $151.32 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $132.86 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $130.46 | 7 | 2025 |
Source payment records
|
|||||
| ABSOLUTE PRO Normalized: absolute pro |
Device | Abbott Laboratories | $120.21 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $105.39 | 4 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $75.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $74.73 | 4 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $68.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $61.12 | 3 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $60.62 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $50.72 | 2 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $41.65 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $33.42 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $26.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $9.62 | 1 | 2025 |
Source payment records
|
|||||
| Orsiro Mission Normalized: orsiro mission |
Device | BIOTRONIK INC. | $3.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 50 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
216 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 548 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 491 | 163 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 253 | 80 |
| Furosemide | Furosemide | 247 | 86 |
| Lisinopril | Lisinopril | 247 | 80 |
| Carvedilol | Carvedilol | 222 | 78 |
| Entresto | Sacubitril/Valsartan | 216 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 60 |
| Eliquis | Apixaban | 175 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 59 |
| Repatha Sureclick | Evolocumab | 164 | 22 |
| Ezetimibe | Ezetimibe | 106 | 32 |
| Losartan Potassium | Losartan Potassium | 96 | 37 |
| Irbesartan | Irbesartan | 65 | 23 |
| Farxiga | Dapagliflozin Propanediol | 62 | 21 |
| Warfarin Sodium | Warfarin Sodium | 59 | 23 |
| Spironolactone | Spironolactone | 53 | 17 |
| Potassium Chloride | Potassium Chloride | 51 | 21 |
| Ranolazine Er | Ranolazine | 49 | 13 |
| Digoxin | Digoxin | 46 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 17 |
| Brilinta | Ticagrelor | 41 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 13 |
| Simvastatin | Simvastatin | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 13 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 18 |
| Cilostazol | Cilostazol | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Prednisone | Prednisone | 15 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85,684.76 · 265 records | Medtronic, Inc. | ABSOLUTE PRO, ALPHAVAC, AMPLATZER TALISMAN, ARTIX MT, AVVIGO Guidance System, Alto Abdominal Stent Graft System, CAMZYOS, CAPVAXIVE, CARDIOMEMS, CARTO 3, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, COREVALVE EVOLUT R, CVI Systems, Coronary Other, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, ENDOCROSS Device, ESPRIT, EVOQUE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FFRct, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, General - Atherectomy, General - Balloon Catheters, General - Stents, General - Therapies, General - Vascular Access, HAWKONE, Kerendia, LANGSTON, LEQVIO, LifeVest, MANTA, MYNX CONTROL VENOUS, NAVITOR, NUVISION ICE CATHETER, ONYX FRONTIER, OPTOWIRE, Orsiro Mission, PASCAL, Paradise Ultrasound Renal Denervation System, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, REPATHA, SAPIEN 3 Ultra RESILIA, SAVVYWIRE, SELUTION SLR PTCA, SYMPHONY CATHETER, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TREO ABDOMINAL STENT-GRAFT SYSTEM, TRICLIP, Torus Stent Graft System, VERQUVO, VYNDAQEL, ZENITH SPIRAL-Z | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error